9 July 2021 (Friday) -ASH Update

The nice people from the American Society of Hematology sent their update today. Perhaps a tad more clinical than I would prefer, but it was all useful reading:

Post-Transplant MRD Monitoring With Non-DTA Mutations Predicts Outcomes in AML In next-generation sequencing-based MRD monitoring, the use of non-DNMT3A, TET2, or ASXL1 mutations may predict relapse and survival following allogeneic hematopoietic cell transplantation for patients with AML.

Are Physician Perceptions of Transfusions a Barrier to Hospice Enrollment for Patients With AML? The tendency of patients with AML and their caregivers to defer end-of-life transfusion decisions to clinicians without participating in shared decision-making may delay hospice admission in patients who would benefit from this care the most.

Survival Outcomes After HLA-Haploidentical Relative Versus Matched Unrelated Donor Transplant in Acute Leukemias and MDS In patients with acute leukemias, those who underwent haploidentical relative hematopoietic cell transplantation had higher rates of grade 3-4 graft-versus-host disease and mortality compared with those who underwent transplant with a matched unrelated donor.